

PF-04753299

## Chemical Properties


CAS No. : 1289620-49-0

Formula: C<sub>18</sub>H<sub>21</sub>NO<sub>4</sub>S

Molecular Weight: 347.43

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	PF-04753299 is a potent and selective inhibitor of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC), demonstrating bactericidal effects against gonococcal isolates and exhibiting inhibitory activity against E. coli, P. aeruginosa, and K. pneumoniae, with minimum inhibitory concentration (MIC) 90 values of 2 µg/ml, 4 µg/ml, and 16 µg/ml, respectively. This compound is utilized in researching gram-negative bacterial infections [1].
Targets(IC50)	Others,Antibacterial
In vivo	Rats were subjected to intraperitoneal challenge with Pseudomonas aeruginosa strain UC12120, a penicillin-resistant, quinolone-susceptible clinical isolate (1a Minimum Inhibitory Concentration MIC = 0.25 µg/mL), at 0.5 hr and 4 hr post-treatment with PF-04753299 (Subcutaneous Dose; Vehicle: 40% β-cyclodextrin dissolved in water). At 24 h post-infection, animals were necropsied and the bacterial load on the spleen was subsequently determined. The dose of compound required to reduce the bacterial load by 50% (ED50) was determined to be 35 mg/kg compared to untreated animals [2].

## Solubility Information

Solubility	DMSO: 70 mg/mL (201.48 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.8783 mL	14.3914 mL	28.7828 mL
5 mM	0.5757 mL	2.8783 mL	5.7566 mL
10 mM	0.2878 mL	1.4391 mL	2.8783 mL
50 mM	0.0576 mL	0.2878 mL	0.5757 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Constance M John, et al. Treatment of human challenge and MDR strains of *Neisseria gonorrhoeae* with LpxC inhibitors. *J Antimicrob Chemother.* 2018 Aug 1;73(8):2064-2071.

Brown MF, et al. Potent inhibitors of LpxC for the treatment of Gram-negative infections. *J Med Chem.* 2012 Jan 26; 55(2):914-23.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481